0878 500 730 - Sofia 0878 500 920 - Varna 0878 500 940 - Burgas 0879 007 420 - Plovdiv 0878 050 042 - Shumen 0878 495 689 - Stara Zagora +38971314005 - Macedonia Office 0878 500 730 - Sofia 0878 500 920 - Varna 0878 500 940 - Burgas 0879 007 420 - Plovdiv 0878 050 042 - Shumen 0878 495 689 - Stara Zagora +38971314005 - Macedonia Office
Registration
Login
Request an appointment
Our offices
Проф. д-р Ердал Карайоз - визитка

Prof. Dr. Erdal Karayoz

Prof. Phd. Erdal Karaöz

BRIEF INFORMATION:
  • Prof. Dr. Erdal Karayoz was born in 1963.
  • Graduation: 1986
  • at the University of Delhi„
Specialist:
regenerative medicine

CV and professional development

Education and academic degrees

  • Master of Histology and Embryology – Dicle University, 1989.

  • Doctorate (PhD) in Histology and Embryology Gazi University, 1994.

  • Associate professorship – Süleyman Demirel University, 1996.

  • Professorship – Suleyman Demirel University, 2002.

  • Professorship – Stem Cell and Gene Therapy Center, Kocaeli University, 2003–2014.

  • Professorship – Istinye University, Faculty of Medicine, 2016–2022.

Professional experience

  • Liv Hospital (Istanbul) – Director of the Center for Regenerative Medicine and Stem Cell Production (2014 – Present).
  • Istinye University – Professor of Histology and Embryology; Vice-Rector (2016-2019); Head of the Center for Stem Cells and Tissue Engineering (2017-2021).
  • Kocaeli University – Professor and Director of the Center for Stem Cells and Gene Therapy (2006–2014).
  • Harvard Medical School – Joslin Diabetes Center (Boston, USA) – guest researcher (2005).
  • Suleyman Demirel University„ – Associate Professor and Professor of Histology and Embryology (1996–2003).
  • Done, Medical Faculty – Specialist in Histology and Embryology (1989–1996).
  • Dicle University – Assistant in Histology and Embryology (1986–1989).

Memberships and publications

  • Member of the Association of Histology and Embryology (1997).
  • Member of the New York Academy of Sciences (1997).
  • Member of the Stereological Association (1999).
  • Member of the Turkish Society of Electron Microscopy (2000).
  • Euroscience, active individual member (2000).
  • Member of the Turkish Society of Hematology (2009).
  • Member of the European Hematology Association (2009).
  • Member of the Association for Cancer Molecular Research (2009).
  • Member of the European Association for Cancer Research (EACR) (2009).
  • Member of the International Society for Cellular Medicine (2010).
  • Association for Organ, Tissue, and Cell Transplantation (Member of the Executive Board, (2013-2014).
  • Association for Stem Cell and Cell Therapies (Executive Board Member, President, 2013-April 2016).
  • Association for Stem Cell and Cell Therapies (Executive Board Member, Vice President, April 2016).

Publications and scientific contributions

  • Author of an 180 scientific publications in international peer-reviewed journals.

  • His articles are cited over 3,600 times, with Hirsch index (h-index) 26, which reflects a significant contribution to the field of regenerative medicine and cell therapy.

  • Participated in multiple clinical trials (phase I) for the application of mesenchymal stem cells in:

    • chronic spinal cord injury,

    • traumatic brain injury,

    • myocardial infarction,

    • autism,

    • Hypoxic-ischemic encephalopathy.

  • His scientific research has been published in prestigious journals, including:
    Stem Cell Research & Therapy, Stem Cell Reviews and Reports, Journal of Cellular and Molecular Medicine, Tissue Engineering and Regenerative Medicine, Archives of Oral Biology, Turkish Journal of Hematology et al.

Scientific and peer-review activities

  • Head and co-author of more than 40 international research projects.

  • Active Reviewer for over 30 international scientific journals in the field of cell biology and regenerative medicine.

Clinical areas of interest

His clinical and scientific work is focused on applying modern cellular technologies for the treatment of:

  • Neurological diseases – autism, epilepsy, multiple sclerosis, cerebral palsy, traumatic brain and spinal cord injuries, hypoxic-ischemic encephalopathy.

  • Musculoskeletal and orthopedic diseases - muscular dystrophy, joint cartilage damage, arthrosis, sports injuries (including tennis elbow).

  • Autoimmune and inflammatory diseases – rheumatoid arthritis, Crohn's disease, chronic inflammatory processes.

  • Metabolic diseases – diabetes mellitus and complications such as diabetic foot.

  • Pulmonary diseases - Chronic obstructive pulmonary disease (COPD), post-COVID damage.

  • Ophthalmological diseases – optical neuropathy, degenerative diseases of the retina and optic nerve.

  • Cardiovascular diseases - myocardial infarction, heart failure.

In addition to his clinical practice, Prof. Dr. Karaoz conducts scientific research in the fields of cell therapy, stem cells, tissue and organ engineering, gene therapies, 3D biotechnologies, and CRISPR-Cas9.

Additional information

Проф. д-р Ердал Карайоз - превю

Prof. Dr. Erdal Karayoz

What methods of treatment does prof. Karayoz in his practice?

There are two different methods of stem cell treatment:

  • Allogeneic - the patient receives stem cells from a suitable donor.
  • Autologous - the patient receives their own.

Prof. Karayoz - methods for allogeneic cell implantation:

  • Allogeneic umbilical cord-derived mesenchymal stem cell MSCs - MSCs have the ability to differentiate into three germ layers, accumulate in damaged tissue or inflamed areas, promote tissue repair, and modulate the immune response. This cell type has many advantages. Mesenchymal stem cells (MSCs) form the group of stem cells that are most commonly used in clinical practice. Much research is being conducted on their regenerative characteristics and it is clear that they have a beneficial effect on the repair processes of many damaged tissues. MSC are used in clinical trials because of their self-regeneration anddifferentiation abilities, their role in tissue repair, and their immunosuppressive and neuroprotective effects.
  • Allogeneic cultured placentas derived from multipotent mesenchymal stromal cells - Using this type of stem cells, one can achieve: improving endothelial function, stimulating angiogenesis and activating the body's own regenerative potential of its own stem cells.

Prof. Karayoz - Methods for autologous cell implantation

  • Stromal Vascular Fraction (SVF)

SVF is derived from the patient's own adipose tissue. Adipose tissue is a rich and very convenient source of stem cells for therapeutic approaches in regenerative medicine. The stromal vascular fraction is a cell extract that is obtained in the laboratory from the body's own fat. SVF cells are obtained by liposuction and contain multiple cell types, including adipose-derived stem cells (ADSCs), mesenchymal and endothelial progenitor cells, leukocyte subtypes, lymphoid cells, pericytes, and vascular smooth muscle cells. SVF cells are processed such that they contain a reproducible and consistent composition of heterogeneous cells. When processed and administered, adipose tissue-derived SVF cells can differentiate into different tissue types, maintain neovascularization, replace cells, and repair traumatic problems.

  • Autologous chondrocyte implantation (ACI)

In this method, mesenchymal stem cells are isolated from the patient's own cartilage tissue. Autologous implantation is a relatively new, advanced procedure used to treat isolated articular cartilage defects of the knee. ACI is also performed for patella (knee cap) defects. Autologous chondrocyte implantation is a two-stage surgical procedure.

First procedure

The first procedure is performed arthroscopically in less than 30 minutes. The surgeon takes a small piece of articular cartilage from the patient's knee. This cartilage biopsy is then sent to a lab where it is enzymatically processed to isolate chondrocytes, which are the cells that produce cartilage. Once these chondrocytes are obtained, they are sent back to the surgeon approximately 6 to 8 weeks later for implantation.

Second stage

The second-stage surgery is an open procedure in which a small patch is sewn over the plastic cartilage defect. The chondrocytes that are collected are injected under this patch, where they adhere to the patient's knee to form what is called hyaline-like cartilage, which resembles the joint's own cartilage. After implantation, there is a period of limited loading for up to 8 weeks. During this time, physical therapy is prescribed to improve range of motion and muscle strength. The surgeon may also recommend the use of robotic passive rehabilitation to ensure the success of the procedure. Return to light sports activities is usually allowed after approximately 6 months with return to full sports activities between 9 and 12 months after the procedure. The overall success rate of ACI is approximately 85%.

How do Prof. Dr. Erdal Karayoz and his colleagues apply stem cells?

Intravenous injection

Based on clinical data and research, stem cells cross the blood-brain barrier when injected systemically.

Procedure

The intravenous delivery method is a very simple process. A catheter is inserted into the patient's vein. Usually, sedation is not required for this procedure. The entire process of intravenous injection of stemhas less than 45 minutes.

Lumbar puncture

Procedure

This is a procedure used to access the cerebrospinal fluid of the brain and spinal cord and helps deliver stem cells directly into the cerebral spinal fluid, bypassing the blood-brain barrier. This is the least invasive method of delivering stem cells directly into the central nervous system.

Intramuscular and intra-articular injection of stem cells

Stem cells are injected directly into the injured muscle or joint.

Work streams:

Part of the team:

Болница Лив 002

Liv Hospital

Liv Hospital's mission is to improve the health of all our international patients by setting the standard of excellence in personalized patient care.

Last viewed in section
"Doctors."

Prof. Dr. Georg Schatzl
Assoc. Prof. Dr. Vahit Mutlu
Dr. Sibel Özdemir
Prof. Dr. Selim Gökçe
Prof. Dr. Bulent Taras
,
Our offices at home and abroad:

Head office Sofia:

Str. General Ivan Kolev, 33 B Bulgaria, Sofia

  • +359 878 500 730
  • +359 879 977 401
  • +359 879 977 402
  • +359 878 500 940
  • +359 878 500 920

Plovdiv office:

Blvd. Hristo Botev 92, RILON Business Centre, floor 2 Bulgaria, Plovdiv

  • +359 879 007 420

Plovdiv Province

  • +359 878 478 045

Smolyan Province:

  • +359 878 471 524

Office Burgas:

Str. Ivan Vazov 75 Bulgaria, Burgas 8000

  • +359 877 500 163

Stara Zagora Office:

2 Zachary Knyazheski Street,
Bulgaria, Stara Zagora

  • +359 878 495 689

Shumen Office:

Str. Panayot Volov No.2 Bulgaria, Shumen.

  • +359 878 050 042

Macedonia Office:

Bane Andreev Ronkata #2, 1400 Veles, Macedonia

  • +38971314005